What IGF-1 Is—and What It Actually Means for a Dog's Aging Muscle

By Arielle Higgins, DVM, MPH

✓ Medically reviewed by Arielle Higgins, DVM, MPH — August 31, 2026 For general education — not a substitute for veterinary care.

Longevity · September 4, 2026 · 6 min read

Population data on IGF-1 explains why your one dog's size predicts more about its aging muscle than its breed name does.

At the population level, dogs with naturally higher circulating IGF-1 grow bigger, faster, and die younger. Narrow that down to the fourteen-year-old terrier or the eight-year-old Great Dane in your living room, and the same hormone explains a good chunk of why one is still trotting around the yard and the other is already losing muscle over its spine. That is the frame worth holding onto before any product claim enters the conversation.

What IGF-1 Actually Does Inside a Muscle Cell

Insulin-like growth factor 1 is a hormone, produced mostly by the liver under growth hormone’s direction, that binds receptors on the surface of muscle fibers. Once bound, it activates signaling cascades that push muscle protein synthesis up and muscle breakdown down. In a growing puppy, that is the machinery building a skeleton and a muscle mass appropriate to the dog’s genetic size. In an aging dog, the same pathway is one of several that quietly loses potency — alongside falling testosterone, more inflammatory cytokine activity, and less efficient motor-unit signaling to type II muscle fibers, according to a summary of canine sarcopenia research published by PetMD. Less IGF-1 signaling does not cause muscle loss on its own, but it removes one of the checks that would otherwise slow it down.

The Gene Behind Size Is the Gene Behind the Trade-Off

Here is the part most owners never hear: a single IGF1 gene variant is a major reason small dogs are small. Researchers who sequenced more than 3,000 dogs across 143 breeds found one IGF1 haplotype common to nearly every small breed and almost absent from giant breeds, as published in Science. That single variant does not just set adult height. It sets a lifelong hormonal baseline — lower circulating IGF-1 in small dogs, higher in large ones — and that baseline follows the dog through every later decade.

A twelve-pound terrier mix and a ninety-pound mastiff came into the same senior wellness appointment three weeks apart, both around age nine, both owned by first-time senior-dog caretakers asking the same question: why does my dog seem to be aging faster than my neighbor’s? The honest answer started with body size, not diet or exercise. The terrier’s baseline IGF-1 profile put her on a trajectory toward a fifteen- or sixteen-year lifespan with muscle loss showing up closer to year twelve. The mastiff, built by the opposite end of the same gene variant, was already showing measurable topline muscle loss at nine — not from anything the owner did wrong, but from the same growth signaling that gave him his size working against him on the back end.

Why Bigger Dogs Trade Growth for Years

This is not a coincidence limited to genetics papers. Higher IGF-1 drives more cell division during growth, and more cell division carries more opportunity for the replication errors that seed cancer — a trade-off described as the “antagonistic pleiotropy” of IGF-1 in aging biology, a concept reviewed in PMC. Large and giant breeds, built on the high-IGF-1 end of that variant, are diagnosed with cancer and other age-related disease earlier and die younger than small breeds sitting on the low-IGF-1 end. It is the same hormone giving a Great Dane its frame and shortening the window it gets to keep that frame.

Where Sarcopenia Actually Fits

Sarcopenia — progressive lean-muscle loss with age — is not caused by low IGF-1 alone, and it is not curable. It is a convergence of hormonal decline, inactivity, and dietary protein that is often inadequate for an aging dog’s needs. Falling IGF-1 signaling is one input among several, which is why a program aimed only at “boosting IGF-1” misses the muscle-loss picture almost entirely. Diet, low-impact activity, and monitoring matter more than any single hormone.

What the Antioxidant and NAD+ Supplement Category Can — and Can’t — Do

Owners chasing IGF-1 numbers usually land in the broader longevity-supplement aisle instead, so it is worth being precise about what that category’s better-studied ingredients actually support. Quercetin, a flavonoid studied for antioxidant and immune-related activity, has evidence at the cellular level; one pharmacology study noted that quercetin formulations and unformulated quercetin, along with NAC and ascorbic acid, “did not affect the feeding behavior of the worms” at the concentrations tested, a modest but real signal that the compound doesn’t disrupt normal biology at dose — Pharmaceuticals (MDPI). Resveratrol’s evidence is similarly early-stage and dose-dependent: one in-vitro study found that “embryonic exposure to ER50 accelerated pupation and adult emergence but shortened adult lifespan,” a reminder that antioxidant compounds are not uniformly protective across every dose and life stage, per Phytomedicine. Neither ingredient restores IGF-1 signaling or reverses sarcopenia. They support general cellular and immune function — nothing more, nothing less — and any product claiming otherwise is outrunning its own citations.

A client called back eighteen months after her ten-year-old Labrador, then 68 pounds, was diagnosed with early sarcopenia. She had started a protein-forward diet and a short daily walk routine, and by day 45 the dog’s hindquarter muscle had visibly filled back in on exam. She’d also added an antioxidant chew on her own, convinced it deserved the credit. It probably supported cellular health at the margins. It did not rebuild that muscle — the protein and the loaded movement did the mechanical work IGF-1 signaling alone could no longer supply.

A Practical Sequence for an Owner Watching Muscle Loss

1. Get a body condition and muscle condition score from your veterinarian before changing anything — visual muscle loss is easy to misjudge from the couch.
2. Confirm dietary protein is adequate for an aging dog’s needs; many senior formulas under-deliver relative to what sarcopenia research recommends.
3. Add low-impact, resistance-style movement — hills, sit-to-stands, slow stairs — rather than just more walking distance.
4. Treat any supplement, antioxidant or otherwise, as a support layer, not a replacement for diet and activity.
5. Recheck muscle condition score every 60–90 days so the plan is judged on the dog’s own trajectory, not a hormone level nobody is actually measuring.

For dogs where slower gait accompanies the muscle loss, it’s worth ruling out whether cold weather is amplifying the stiffness before assuming it’s purely sarcopenia. Sudden hind-end weakness deserves a same-day look, not a supplement — see why a dog’s back legs give out for the physiology-first version of that triage. If a NAD+ chew is part of the plan, it’s reasonable to ask what that actually costs per month for a large dog before committing. And because immune and muscle support often get bundled in marketing, it helps to separate the two using a dedicated guide to senior immune support.

The Verdict

IGF-1 is not a supplement target. It is a baseline set mostly by genetics and body size, and it is one input into muscle loss among several that matter more day to day: dietary protein, resistance-style activity, and veterinary monitoring. Large-breed owners should expect the muscle-loss conversation to start earlier; small-breed owners should expect it later but not assume it won’t come. The population-level trade-off is real. What a single dog does about it is still mostly diet and movement, not a hormone number on a lab panel nobody runs in general practice anyway.

So where does that leave the dog on your floor right now — is the muscle loss you’re seeing a size-driven timeline playing out on schedule, or a sign that diet and activity need to change first?